Advertisement

Topics

AZ and Merck & Co ovarian cancer drug gets expanded US use

06:00 EDT 18 Aug 2017 | pharmaphorum

AstraZeneca and Merck & Co’s partnership to develop ovarian cancer drug Lynparza has got off to a good start after the FDA approved its use in a wider group of women. The drug has been approved for women with platinum-sensitive recurrent ova...

Original Article: AZ and Merck & Co ovarian cancer drug gets expanded US use

NEXT ARTICLE

More From BioPortfolio on "AZ and Merck & Co ovarian cancer drug gets expanded US use"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...